within Pharmacolibrary.Drugs.ATC.N;

model N04BC01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.065,
    Cl             = 0.08499999999999999,
    adminDuration  = 600,
    adminMass      = 0.005,
    adminCount     = 1,
    Vd             = 0.095,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.006833333333333333,
    Tlag           = 900
  );

  annotation(Documentation(
    info ="<html><body><p>Bromocriptine is a dopamine D2 receptor agonist derived from ergot, mainly used for the treatment of Parkinsonâ€™s disease, hyperprolactinemia, acromegaly, and type 2 diabetes. It is approved and currently used in clinical practice for these indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers (both male and female) after single oral doses.</p><h4>References</h4><ol><li>J Kanto,Clinical pharmacokinetics of ergotamine, dihydroergotamine, ergotoxine, bromocriptine, methysergide, and lergotrile.,International journal of clinical pharmacology, therapy, and toxicology,1983<a href='https://pubmed.ncbi.nlm.nih.gov/6133838/'>https://pubmed.ncbi.nlm.nih.gov/6133838/</a></li><li>H F Schran, S I Bhuta, H J Schwarz, M O Thorner,The pharmacokinetics of bromocriptine in man.,Advances in biochemical psychopharmacology,1980<a href='https://pubmed.ncbi.nlm.nih.gov/7395607/'>https://pubmed.ncbi.nlm.nih.gov/7395607/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N04BC01;
